Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids

Philipp Markart, Clemens Ruppert, Malgorzata Wygrecka, Thorsten Colaris, Bhola Dahal, Dieter Walmrath, Heinz Harbach, Jochen Wilhelm, Werner Seeger, Reinhold Schmidt, Andreas Guenther

Background: Extensive biochemical and biophysical changes of the pulmonary surfactant system occur in the acute respiratory distress syndrome (ARDS).

Methods: The effect of intrabronchial administration of a recombinant surfactant protein C-based surfactant preparation (Venticute) on gas exchange, surfactant composition and function was investigated in 31 patients with ARDS in a randomised controlled phase I/II clinical pilot trial. Bronchoalveolar lavage fluids for surfactant analysis were obtained 3 h before and 48 and 120 h after the first surfactant application. Potentially deleterious effects of surfactant neutral lipids in patients with ARDS were also identified.

Results: Before treatment all patients had marked abnormalities in the surfactant phospholipid and protein composition. In response to surfactant treatment, gas exchange improved and surfactant phospholipid and protein content were almost normalised. Alveolar surface activity was dramatically impaired before treatment and only partially improved after surfactant administration. Further analysis of the bronchoalveolar lavage fluids revealed a twofold increase in neutral lipid content and altered neutral lipid profile in patients with ARDS compared with healthy controls. These differences persisted even after administration of large amounts of Venticute. Supplementation of Venticute or natural surfactant with a synthetic neutral lipid preparation, mimicking the profile in ARDS, caused a dose-dependent deterioration of surface activity in vitro.

Conclusion: Intrabronchial surfactant treatment improves gas exchange in ARDS, but the efficacy may be limited by increased concentration and altered neutral lipid profile in surfactant under these conditions.

Pulmonary surfactant is a lipoprotein complex consisting of lipids (90%) and proteins (10%). Surfactant reduces the alveolar surface tension to near 0 mN/m, preventing alveolar collapse, and enables gas exchange and alveolar ventilation at physiological transpulmonary pressure gradients. Approximately 80–90% of the lipids are phospholipids. Four surfactant proteins (SP) have been identified (SP-A, SP-B, SP-C and SP-D). Surfactant obtained by bronchoalveolar lavage (BAL) can be separated into different subfractions by buoyant density gradient or differential centrifugation. The large surfactant aggregate (LA) fraction, consisting of lamellar bodies, tubular myelin and large multilamellar vesicles, displays excellent biophysical activity in vitro and in vivo and represents the precursor fraction of the interfacial surface film. In patients with the acute respiratory distress syndrome (ARDS), extensive alterations of biochemical and biophysical surfactant properties have been described. In addition, intrabronchial surfactant administration was shown to be beneficial in different ARDS models. Impaired surfactant function may therefore play a role in the development of gas exchange abnormalities in clinical ARDS. Accordingly, in some recent phase II and phase III clinical trials, administration of surfactant in subjects with ARDS significantly improved arterial oxygenation and surfactant composition.

In the present study we investigated surfactant abnormalities in the BAL fluids of patients with ARDS participating in a randomised controlled phase I/II study in Europe/South Africa addressing the safety and efficacy of a recombinant SP-C-based surfactant (Venticute). Before randomisation, profound surfactant abnormalities were encountered, with a marked loss of surface tension-lowering properties and severe alterations in phospholipid, fatty acid and surfactant protein composition. In response to surfactant treatment, gas exchange was improved and phospholipid, fatty acid profiles and SP-C content were nearly normalised, but surface activity was only partially restored. To investigate the underlying mechanism for this partial restoration, we further analysed the LA fraction from the BAL fluids. Interestingly, we observed a twofold increase in the relative amount of neutral lipids in the LA fraction of patients with ARDS. Physiologically, neutral lipids represent 10–20% of the BAL fluid lipids and about 5% of the LA lipids. Within the LA fraction, the neutral lipids consist of cholesterol (30–40% of total neutral lipids), free fatty acids (25–30%), cholesterol ester (~12%), monoglycerides (10–15%), diglycerides (~14%) and triglycerides (~8%). The increased concentration of neutral lipids in the LA fraction of subjects with ARDS was still present after administration of large amounts of Venticute. Moreover, the composition of the neutral lipid fraction was markedly different between subjects with ARDS and healthy controls. Reconstitution of Venticute or a natural surfactant preparation with a neutral lipid preparation, mimicking the profile in subjects with ARDS, provoked a dose-dependent inhibition of surfactant function in vitro. This effect was already evident at a relatively neutral lipid dose found in patients with ARDS.

Abbreviations: ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; PaO2, fractional inspired oxygen; γ, surface tension after 1/2 s of film oscillation; γmin, surface tension values after 5 min of film oscillation at minimum bubble radius; HPTLC, high-performance thin-layer chromatography; LA, large surfactant aggregate; PaCO2, arterial oxygen tension; SP, surfactant protein
Changes in quantity and composition of the surfactant neutral lipids may thus contribute to the impairment of surface activity and gas exchange abnormalities in ARDS.

METHODS

Study design

Thirty-one patients with ARDS as defined by the American-European Consensus criteria for a maximum of 120 h since diagnosis (early ARDS) were investigated. All patients with ARDS participated in a randomised multicentre controlled phase I/II pilot study investigating the safety and efficacy of an intrabronchial administration of a recombinant SP-C-based surfactant (Venticute). Efficacy was assessed by calculating (1) the excess area under the arterial oxygen tension/fractional inspired oxygen (PaO2/FIO2) curve during the 24 h after administration of the first drug dose and (2) the number of days with unassisted breathing within the 28 day observation period and comparing these variables among groups. Another objective of the study was to assess BAL fluid recovered from the patients for surfactant components and function.

During a 6 h baseline period, clinical and respiratory parameters were recorded and the first BAL fluid sample (≈3 h) for surfactant analyses was obtained. Baseline demographic and physiological data for each of the patient groups are shown in table 1. No significant differences were detected between groups. Values for the modified Acute Physiology and Chronic Health Evaluation (APACHE) II score and for baseline PaO2/FIO2 and PEEP values represent the mean of three readings over the 6 h baseline period.

<table>
<thead>
<tr>
<th>Table 1 Baseline demographic and physiological data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
</tr>
<tr>
<td>Ethnic origin, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Predisposing events, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Hours from diagnosis</td>
</tr>
<tr>
<td>To initial treatment</td>
</tr>
<tr>
<td>PEEP (cm H2O)</td>
</tr>
<tr>
<td>PaO2/FIO2</td>
</tr>
</tbody>
</table>

Data are presented as median (25–75th percentile).

In vitro experiments with neutral lipids and surfactant preparations

Preparation of a rabbit BAL fluid pool

Healthy rabbits of either sex were killed by intravenous application of a lethal dose of pentobarbital/ketanest. A catheter was placed into the trachea and the lungs were lavaged three times with 50 ml 0.9% NaCl. After filtration of the lavage fluid through sterile gauze and sedimentation of cells (200 g, 4°C, 10 min), supernatants originating from 20 rabbits were pooled and then centrifuged at 48 000 g (4°C, 1 h). The pellet represents the LA fraction and was resuspended in a small volume of 0.9% NaCl/3 mM CaCl2 and adjusted to a stock concentration of 2 mg/ml phospholipids was used.

Recombinant SP-C-based surfactant preparation

The recombinant SP-C-based surfactant preparation used for the in vitro experiments was identical to the study drug material and was donated by ALTANA Pharma AG, Konstanz, Germany. The recombinant SP-C-based surfactant preparation contains dipalmitoylphosphatidylcholine and phosphatidylglycerol (7:3 wt/wt), enriched with 5% (wt/wt) palmitic acid and 2% (wt/wt) recombinant human SP-C. A stock preparation containing 2 mg/ml phospholipids was used.

Neutral lipid preparation

The neutral lipid preparations used for the in vitro experiments were designed to mimic the neutral lipid profile in patients with ARDS and consisted either of 100% or 50% unsaturated fatty acids. Increasing amounts of a 1 mg/ml stock solution were added to the neutral lipid containing 2 mg/ml phospholipids was used.

Surfactant analysis

Isolation of large surfactant aggregates (LA)

BAL fluid from patients with ARDS, those with cardiogenic pulmonary oedema or healthy volunteers was centrifuged at 48 000 g (4°C, 1 h). The resulting pellet containing the LA fraction was resuspended in a small volume of 0.9% NaCl/3 mM CaCl2 and adjusted to a phospholipid concentration of 2 mg/ml. In parallel experiments, the LA fraction from seven patients with ARDS was further purified by sucrose gradient centrifugation as described in detail previously.

Phospholipid and fatty acid analysis

Lipids were extracted with chloroform/methanol according to method of Bligh and Dyer and the phospholipid content was determined by spectrophotometric measurement of phosphorus. For separation and analysis of phospholipid classes,
Analysis of data

Data are given as median and interquartile range. The box and whisker plots indicate the median, 1st and 3rd quartiles; the whiskers are extended to the most extreme value inside the 1.5-fold interquartile range. Values outside (potential outliers) are indicated by circles. The statistical analyses were performed in R Version 2.3.1. Deviations from the normal distribution were tested using the Shapiro–Wilk test. The comparability of data sets to justify a combination was tested with the F-test or Wilcoxon rank sum tests, respectively. The p values of multiple comparisons were corrected with the algorithm of Benjamini-Hochberg to control the false discovery rate. Categorical data were tested for independence in contingency tables employing Fisher’s exact test. The distribution of the outcomes between the groups (alive, weaned and alive) was tested using the χ² goodness-of-fit test against the null hypothesis of a uniform distribution. All tests were performed with an undirected hypothesis (two-sided). The level of statistical significance was set at 5%.

RESULTS

Gas exchange, biochemical and biophysical surfactant properties on surfactant treatment

Patients with early ARDS were treated up to four times by intrabronchial administration of 1 ml recombinant SP-C surfactant (containing 1 mg recombinant SP-C + 50 mg phospholipid/kg lean body weight). A significant improvement in PaO₂/FIO₂ ratios at 48 h (p = 0.008) and 120 h (p = 0.0005) after initial treatment was observed (table 2). The value for the excess area under the PaO₂/FIO₂ curve during the 24 h after administration of the first drug dose was also higher in the surfactant treatment group than in patients receiving standard care only (402 vs 220 mm Hg/h; see table S2 in the online data supplement available at http://thorax.bmj.com/supplemental); however, this difference did not reach statistical significance, probably due to small sample sizes. Further study results are summarised in table S2 in the online data supplement (http://thorax.bmj.com/supplemental). In addition to the improvements in gas exchange, surfactant treatment produced a far-reaching restoration of key biochemical surfactant properties (table 2). In detail, the concentration of phospholipids was markedly increased in total BAL fluid, and the relative amount of the LA fraction was nearly normalised. Moreover, the relative amount of phosphatidylglycerol and the degree of palmitoylation in phosphatidylcholine were both fully normalised upon surfactant application, and the concentration of SP-C in total BAL fluid was greatly increased (table 2). No significant differences in BAL fluid concentrations of SP-A, SP-B or SP-D were detected between the standard care group and the surfactant treatment group (data not shown).

In contrast to the complete normalisation of the phospholipid and fatty acid profiles, surface tension values after 5 min of film oscillation (γmin, fig 1) and after 12 s of film adsorption (γads, data not shown) were significantly improved in the patients receiving surfactant treatment (p = 0.02 at 48 h, p = 0.04 at 120 h), although not to values observed for healthy subjects. This observation was made in LA obtained by either high speed centrifugation (as depicted in fig 1) or by sucrose gradient centrifugation (data not shown).

Table 2: Biochemical surfactant properties and gas exchange in healthy controls and patients with acute respiratory distress syndrome (ARDS) receiving either standard care or additional surfactant treatment

<table>
<thead>
<tr>
<th>ARDS</th>
<th>Control</th>
<th>Baseline</th>
<th>-48 h</th>
<th>+120 h</th>
<th>Surfactant treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>+48 h</td>
<td>+120 h</td>
<td></td>
</tr>
<tr>
<td>LA (% of PL)</td>
<td>79.1 (70.5–86.5)</td>
<td>45.4 (28.8–53.2)</td>
<td>27.4 (23.2–52.2)</td>
<td>30.5 (25.8–31.10)</td>
<td>73.5 (68.3–77.2)** 64.2 (55.3–75.2)</td>
</tr>
<tr>
<td>PL (µg/ml)</td>
<td>23.5 (17.2–29.8)</td>
<td>23.6 (14.5–44.6)</td>
<td>30.4 (15.2–42.1)</td>
<td>17.0 (9.6–25.4)</td>
<td>185.0 (44.8–230.0)** 48.4 (31.6–78.1)</td>
</tr>
<tr>
<td>PC (% of total PL)</td>
<td>80.0 (79.0–82.3)</td>
<td>77.9 (70.3–81.6)</td>
<td>81.1 (73.2–83.1)</td>
<td>81.9 (80.6–85.3)</td>
<td>77.6 (68.1–83.5) 72.9 (66.6–78.1)</td>
</tr>
<tr>
<td>PG (% of total PL)</td>
<td>11.8 (11.3–12.7)</td>
<td>1.6 (1.2–2.6)</td>
<td>1.9 (0.7–5.5)</td>
<td>2.1 (0.8–2.3)</td>
<td>15.7 (8.9–21.8)** 6.8 (5.3–13.7)**</td>
</tr>
<tr>
<td>Palmitic acid</td>
<td>74.2 (71.4–77.1)</td>
<td>53.6 (44.8–59.2)</td>
<td>52.6 (50.3–57.4)</td>
<td>57.8 (56.3–59.2)</td>
<td>85.6 (77.8–89.4)** 84.1 (78.5–84.7)**</td>
</tr>
<tr>
<td>Palmitoleic acid (% of PC fatty acids)</td>
<td>4.2 (2.8–5.5)</td>
<td>3.5 (2.4–4.5)</td>
<td>3.6 (3.0–4.9)</td>
<td>3.7 (3.0–4.9)</td>
<td>4.1 (3.0–4.9) 3.8 (3.0–4.9)</td>
</tr>
<tr>
<td>SF-C (µg/ml)</td>
<td>494.9 (397.0–601.0)</td>
<td>350.2 (212.4–724.3)</td>
<td>437.0 (250.0–657.0)</td>
<td>436.0 (284.0–760.0)</td>
<td>1970.0 (770.0–2490.0)** 717.0 (290.0–1160.0)</td>
</tr>
<tr>
<td>PafCo/FIO₂ (mm Hg)</td>
<td>461.0 (446.0–469.0)</td>
<td>126.5 (103–149.7)</td>
<td>134.0 (94.1–164.0)</td>
<td>156.0 (85.0–215.0)</td>
<td>143.0 (138.0–182.0)** 121.0 (116.0–250.0)**</td>
</tr>
</tbody>
</table>

Data are presented as median (25–75th percentile). LA, large surfactant aggregate fraction; PL, phospholipids; PC, phosphatidylcholine; PG, phosphatidylglycerol; SP-C, surfactant protein C; PafCo/FIO₂, arterial oxygen tension/fractional oxygen inspiration.

*p<0.05; **p<0.01; ***p<0.001 pre-treatment vs post-treatment.
Neutral lipid content and profile of the LA fraction

To investigate the underlying mechanism for the partial restoration of surface activity, we further analysed the LA fraction from the BAL fluids for neutral lipid levels and profiles. Compared with healthy controls, the relative amount of neutral lipids within the LA fraction was significantly increased in the initial BAL fluid samples of the patients with ARDS at baseline ($p = 0.0005$), and no major changes were noted over the subsequent 120 h observation period, regardless of whether the patients received standard care only ($p=0.001$ at 48 h) or standard care + Venticute ($p = 0.013$ at 48 h, $p<0.001$ at 120 h; fig 2). Taking into consideration the absolute amount of phospholipids in the BAL fluid and the relative LA content, the median concentration of LA-related neutral lipids was 11.1 mg/ml (interquartile range 2.1–19.2) 48 h after surfactant treatment and 2.7 mg/ml (interquartile range 1.4–6.5) 120 h after treatment, and thus several fold higher in the ARDS-surfactant group compared with the pre-treatment data (baseline) and the ARDS-standard care group. Analogous data were obtained when the LA fraction was analysed after isolation by high speed centrifugation from healthy controls, patients with ARDS before (−3 h = baseline) and after intrabronchial administration of 1 ml recombinant SP-C surfactant (containing 1 mg recombinant SP-C + 50 mg phospholipid)/kg lean body weight given up to four times, and from patients with ARDS receiving standard care only is given. The box-and-whisker plots indicate the median, 1st and 3rd quartiles; the whiskers are extended to the most extreme value inside the 1.5-fold interquartile range. Values outside (potential outliers) are indicated by circles. The significance level is indicated by * $p = 0.02$ (at 48 h) and $p = 0.04$ (at 120 h; all versus baseline values).

Impact of neutral lipids on the surface activity of different surfactant preparations in vitro

The potential impact of neutral lipid mixtures—mimicking the neutral lipid profile in patients with ARDS—on the surface activity of different surfactant preparations was then investigated. Addition of increasing amounts of a completely unsaturated neutral lipid mixture to the recombinant SP-C surfactant or to a natural rabbit LA preparation resulted in a dose-dependent increase of $\gamma_{\text{ads}}$ in almost 20 mN/m in both surfactant preparations (fig 4). $\gamma_{\text{ads}}$ values were only slightly increased in the presence of increasing amounts of neutral lipids (see fig S1 in online data supplement available at http://thorax.bmj.com/ supplemental). A neutral lipid mixture consisting of 50% unsaturated fatty acids exhibited a similar inhibitory effect on the biophysical activity of the recombinant SP-C surfactant (fig 4 and fig S1 of the online data supplement available at http://thorax.bmj.com/ supplemental).

In order to define the putative surfactant inhibitory effect of each component of the neutral lipid mixtures more precisely, we investigated the influence of increasing amounts of single neutral lipids on the surface activity of the recombinant SP-C surfactant. Diglycerides and, to a lesser degree, free fatty acids showed a marked inhibitory effect on the $\gamma_{\text{ads}}$ values (fig 5). Interestingly, two different neutral lipids—monoglycerides and cholesterol—were the most effective in inhibiting the $\gamma_{\text{ads}}$ values (fig S2 of the online data supplement available at http://thorax.bmj.com/ supplemental).
DISCUSSION

In this study we have investigated the effect of intrabronchial administration of a recombinant SP-C-based surfactant (Ventintute) on gas exchange, surfactant composition and function of 31 patients with ARDS. All patients participated in a randomised controlled multicentre phase I/II study in Europe/South Africa addressing the safety and efficacy of this surfactant preparation in ARDS. The study was performed in parallel to an almost identical trial in North America.13 In accordance with some former studies, a significant improvement was seen in gas exchange in the early period after surfactant administration. At baseline the BAL fluid concentrations of total phospholipids, phosphatidylglycerol and SP-C, the relative amount of the LA fraction and the degree of palmitoylation in phosphatidylcholine were all significantly decreased in patients with ARDS. Following administration of the recombinant SP-C surfactant all parameters were almost fully normalised, which paralleled the improvement in gas exchange. Surfactant treatment favourably decreased the raised minimal surface tension values of the LA fraction, although the values were still considerably higher than the ranges normally observed in healthy controls. As the applied material itself is known to possess excellent surface activity and, in addition, the far-reaching normalisation of biochemical parameters implies that the exogenous surfactant material successfully merged with the endogenous pool, there are only a few possible explanations for the limited improvement in surface activity in response to surfactant administration:

First, it could be argued that inhibitors of surfactant function (particularly plasma proteins such as fibrinogen)26 are largely responsible for the incomplete restoration of surface activity with surfactant treatment. However, we have used two different techniques—high speed centrifugation and sucrose gradient centrifugation—to isolate the LA fraction from BAL fluid, thereby separating the LA fraction from proteinaceous material and other inhibitors. Protein recovery in the LA fraction was 2.7% with centrifugation at 48 000 g and >0.5% with sucrose gradient centrifugation (data not shown).7 As the surface activity of the LA fraction obtained by the two methods deteriorated to the same extent and as there was no appreciable contamination of the lipid fraction with lypoPC, platelet-activating factor or proteins, we think that inhibitory phenomena are unlikely to explain the incomplete restoration of surface activity of the LA fraction. Nevertheless, we would anticipate that the "true" alveolar surface tension of patients with ARDS, both before and after surfactant treatment, is higher as a result of the presence of these inhibitors, as suggested in previous reports.7

Second, it might be argued that the lack of SP-B was responsible for the incomplete improvement in surface activity. However, numerous studies have shown that SP-C-based surfactants such as the recombinant SP-C surfactant achieve similar low surface tension values in vitro and similar efficacy in vivo to that of natural surfactant extracts containing both hydrophobic surfactant proteins.27–29 Nevertheless, this issue may be of some importance in the presence of inhibitors where SP-B-based surfactants have been shown to display better surface activity than SP-C-based surfactants.27–29 However, as discussed above, the isolated LA fractions were almost completely separated from potential inhibitors. We therefore think that this issue is not of major importance.

Figure 3 Neutral lipid profile of the large surfactant aggregate (LA) fraction of healthy controls and patients with acute respiratory distress syndrome (ARDS). The content of different neutral lipid classes (% of total neutral lipids, wt/wt) in the LA fraction obtained by high speed centrifugation from healthy controls, from patients with ARDS before treatment (average value = baseline) and from patients with ARDS receiving standard care or additional treatment with 1 ml recombinant SP-C surfactant (containing 1 mg recombinant SP-C + 50 mg phospholipid)/kg lean body weight given up to four times at 48 h after initial treatment is given. The box-and-whisker plots indicate the median, 1st and 3rd quartiles; the whiskers are extended to the most extreme value inside the 1.5-fold interquartile range. The significance level is indicated by *p<0.05; **p<0.01; ***p<0.001 (patients with ARDS pre or post standard or surfactant treatment vs healthy controls). MG, monoglycerides; DG, diglycerides; Chol, cholesterol; FFA, free fatty acids; TG, triglycerides; C-E, cholesterol ester; NL, neutral lipids.

Figure 4 Influence of neutral lipids on the surface activity of a recombinant surfactant protein (SP)-C-based surfactant preparation and of the large surfactant aggregate (LA) fraction of natural rabbit lung surfactant. A neutral lipid mixture containing 100% unsaturated neutral lipids and mimicking the neutral lipid profile in patients with acute respiratory distress syndrome (ARDS) was added in increasing amounts (0–25% of phospholipids, wt/wt) to 2 mg/ml recombinant SP-C surfactant (squares) and to 2 mg/ml of the LA fraction of natural rabbit lung surfactant (circles). A neutral lipid mixture containing 50% unsaturated neutral lipids was also added in increasing amounts to recombinant SP-C surfactant (triangles). The surface tension values after 5 min of film oscillation at minimum bubble radius (cmin) are given. Data are given as median values (n = 8 for each concentration). NL, neutral lipids; PL, phospholipids.
Neutral lipids have been known for a long time to be an integral component of the pulmonary surfactant system. They are actively secreted within the lamellar bodies from type II cells, but their precise role within the surfactant system is still unclear. In particular, data are scarce in view of the regulation and role of neutral lipids in acute respiratory failure. Alveolar cholesterol was found to be increased in some animal models of acute lung injury but neutral lipids have never been investigated in patients with ARDS. It has recently been shown that cholesterol plays a critical role in promoting the lateral organisation of bilayer membranes made of native pulmonary surfactant. Furthermore, neutral lipids such as cholesterol enhance adsorption at the air-water interface and also improve film respreading of dipalmitoylphosphatidylcholine or more complex phospholipid films, thus improving surface activity. However, neutral lipids were much less effective in enhancing adsorption than the hydrophobic surfactant proteins SP-B and SP-C. In oscillating bubble studies, in contrast to mixtures of phospholipids and hydrophobic surfactant proteins, a protein-free mixture consisting of phospholipids and neutral lipids never reached a minimum surface tension of <20 mN/m.

Fourth, there was a marked increase in neutral lipids in the LA fraction of subjects with ARDS, but no significant difference between the neutral lipid content in the BAL fluids of patients with ARDS following surfactant treatment (p = 0.003 at 48 h). However, it is possible that some of this exogenously administered protein is degraded by the action of activated polymorphonuclear neutrophils and this may contribute to the limited improvement in surface activity in response to surfactant treatment.

The source of increased neutral lipids and altered composition in ARDS is presently unknown. One possibility is altered synthesis or secretion by type II cells. Alternatively, changes may be due to spillover of neutral lipids from the systemic circulation via a leaky endothelial and epithelial barrier. However, the plasma neutral lipid profile is characterised by a large amount of cholesterol ester (46%) and diglycerides (30%), whereas only traces of free fatty acids, monoglycerides and diglycerides can be detected. The plasma neutral lipid profile is thus strikingly different from the neutral lipid profile in the LA fraction, regardless of whether the LA fraction was obtained by high speed centrifugation or further purified from blood contaminants by sucrose gradient centrifugation. Thus, “contamination” by plasma-derived neutral lipids seems unlikely. Moreover, if the type II cell is indeed the main source of increased neutral lipids in ARDS, our observation of a persistently raised neutral lipid content despite application of large amounts of exogenous surfactant material would suggest the existence of a mechanism that maintains a particular neutral lipid/phospholipid ratio in the acutely injured lung.

We conclude that increased levels and an altered neutral lipid profile may contribute to the impairment of surface activity in ARDS. Remarkably, neutral lipid abnormalities of the LA fraction were found to persist even after intratracheal surfactant administration and may prevent full normalisation of the alveolar surface tension by surfactant treatment. Further studies are needed to address the mechanisms underlying the disturbances in surfactant neutral lipid homeostasis in ARDS.
One implication of this study would be to test if neutral lipid-free exogenous surfactant preparations are more suitable for the treatment of ARDS.

ACKNOWLEDGEMENTS

The authors thank all the European/South African clinical centres that participated in the Venticute phase I/II trial and Leigh Marsh for proofreading the manuscript.

Additional information is provided in the online data supplement available at http://thorax.bmj.com/supplemental.

Authors’ affiliations
Philipp Markart, Clemens Ruppert, Bhola Dahal, Dieter Walmrath, Jochen Wilhelm, Werner Seeger, Reinhold Schmidt, Andreas Guenther, Departments of Internal Medicine, Intensive Care Medicine and Pain Therapy, Faculty of Medicine, University of Giessen Lung Center, Giessen, Germany
Malgorzata Wygrecka, Departments of Biochemistry, Intensive Care Medicine and Pain Therapy, Faculty of Medicine, University of Giessen Lung Center, Giessen, Germany
Thorsten Colaris, Heinz Harbach, Departments of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Faculty of Medicine, University of Giessen Lung Center, Giessen, Germany

This study was supported by Deutsche Forschungsgemeinschaft (DFG), SFB 547, SCHM 1524/2-1, ALTANA Pharma AG, Konstanz, Germany

Competing interests: WS receives grant and contract support and fees for consulting services by the following companies: Schering AG, Pfizer Ltd, Altana Pharma AG, Lung Rx, Myogen. None of the other authors has any financial relationship with a commercial entity that has an interest in the subject matter or materials discussed in the manuscript.

The study was approved by local institutional review boards/ethics committees at each participating institution and informed consent was obtained from all patients or their legal representatives.

REFERENCES